Results 111 to 120 of about 2,581 (157)

Treatment with CFTR Modulators for Cystic Fibrosis: What a Pediatric Gastroenterologist Needs to Know. [PDF]

Children (Basel)
Jimenez DG, García Romero R, Martínez AR, Vicente Santamaria S.   +3 more
europepmc   +1 more source

Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of lumacaftor ivacaftor therapy based on real-world data. [PDF]

Sci Rep
Imrei M, Kéri AF, Gács É, Gönczi I, Meláth M, Kosaras É, Demeter B, Péterfia C, Vass K, Székely G, Ocskay K, Párniczky A.   +11 more
europepmc   +1 more source

Lumacaftor/ivacaftor for cystic fibrosis.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ivacaftor/lumacaftor

Reactions Weekly, 2019
  +8 more sources

Ivacaftor/lumacaftor

Reactions Weekly, 2017
  +9 more sources

Ivacaftor/lumacaftor

Reactions Weekly, 2021
  +4 more sources

Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis

Pediatric Pulmonology, 2018
AbstractBackgroundCystic fibrosis (CF) is a life‐limiting disease caused by a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Lumacaftor/Ivacaftor is a novel CFTR modulator approved for patients that are homozygous for Phe508del CFTR, but its clinical effectiveness varies amongst patients, making it difficult to determine
Benjamin T. Kopp, Scott McCulloch, Chandra L. Shrestha, Shuzhong Zhang, Lisa Sarzynski, Frederick W. Woodley, Don Hayes   +6 more
openaire   +2 more sources